This is supported by recent research; a nationwide study found that SGLT2 inhibitors significantly reduced amputation rates in patients with diabetes‐related foot disease compared to incretin‐based therapies,29 whilst another study demonstrated lower amputation risks associated with SGLT2 inhibitors compared to DPP‐4 inhibitors across various patient cohorts.30 Here, DPP4 is linked to diabetes mellitus.